Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria

BACKGROUND: The administration of calcineurin inhibitors (CNIs) posttransplant has been implicated as an independent risk factor for the recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT). The new immunosuppressive agent sirolimus (SRL) acts as a primary immunosuppressant...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ann Transl Med
Autori principali: Ling, Sunbin, Feng, Tingting, Zhan, Qifan, Duan, Xin, Jiang, Guangjiang, Shen, Tian, Shan, Qiaonan, Xu, Shengjun, Ye, Qianwei, Liu, Peng, Cen, Beini, Zheng, Shusen, Xu, Xiao
Natura: Artigo
Lingua:Inglês
Pubblicazione: AME Publishing Company 2020
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049005/
https://ncbi.nlm.nih.gov/pubmed/32175373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2020.01.10
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi